Immunomodulator II patent grant further strengthens robust intellectual property portfolio for partnering
Poolbeg Pharma PLC (AIM:POLB) Option Agreement to Acquire Orphan Drug Candidate
Poolbeg Pharma PLC (AIM: POLB, OTCQB: POLBF) has secured an exclusive 12-month option agreement with Silk Road Therapeutics Inc to acquire a phase III-ready oral ulcer treatment for Behçet’s Disease.
Poolbeg Pharma PLC – Results for the year ended 31 December 2023
Significant pipeline advancements Strategic expansion into cancer immunotherapy-induced CRS unlocking a market opportunity exceeding US$10Bn Key senior management hires
Poolbeg Pharma PLC (AIM:POLB) POLB 001 US Patent Update
Notice of Allowance for Significant POLB 001 Patent in the United States Notice of Allowance for Immunomodulator II further strengthens robust intellectual property portfolio
Poolbeg Pharma PLC (AIM:POLB) Director/PDMR Shareholding
22 February 2024 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has received
Poolbeg Pharma PLC (AIM:POLB) Director Share Purchase
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has received notification on
Poolbeg Pharma PLC (AIM:POLB) Board Role Change and Launch of EIP
Board Role Change and Launch of Employee Performance Incentive Plan
Poolbeg Pharma PLC (AIM:POLB) Market Opportunity for POLB 001 for CRS
Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)
Poolbeg Pharma PLC (AIM:POLB) Further data shows POLB001 potential in cancer CRS
Further Data Confirms POLB 001’s Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS) Market opportunity estimated to be greater than US$1 billion
Poolbeg Pharma PLC (AIM:POLB) RSV AI Drug Candidate Analysis Update
Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AI RSV drug candidates with the highest probability of success prioritised
Poolbeg Pharma PLC – POLB 001 Data Presented at ASH
POLB 001 – targeting Cytokine Release Syndrome (CRS) associated with cancer immunotherapies
Poolbeg Pharma PLC (AIM:POLB) Directorate Change
Poolbeg Pharma PLC (AIM: POLB, OTCQB: POLBF) has announced the resignation of Patrick Ashe, an independent director who played a pivotal role in guiding the company through its early stages